Business Context and Reporting Period
Company: Teradyne, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 4, 2009
Business Overview: Teradyne is a global supplier of automatic test equipment, operating through two primary segments: Semiconductor Test and Systems Test Group (which includes Military/Aerospace, Commercial Board Test, Diagnostic Solutions, and Hard Disk Drive test systems).
Key Financial Metrics
Revenue (Nine Months Ended Oct 4, 2009): $552.4 million (down 39.5% from $912.3 million in the prior year period).
Net Income/Loss: Net loss of $150.8 million for the nine months ended Oct 4, 2009, compared to a net loss of $9.2 million in the prior year. For the quarter ended Oct 4, 2009, the company reported a net income of $6.7 million.
Gross Profit: $187.2 million for the nine months (33.9% margin), down from $420.3 million (46.1% margin) in the prior year.
Operating Cash Flow: Net cash provided by operating activities was $56.2 million for the nine months ended Oct 4, 2009.
Liquidity: Cash and cash equivalents totaled $406.7 million as of Oct 4, 2009. Total cash, cash equivalents, and marketable securities were approximately $467.5 million.
Debt: Long-term debt increased to $139.0 million, primarily due to the issuance of $190 million in convertible senior notes in April 2009. The company repaid its $122.5 million revolving credit facility in April 2009.
Material Changes vs. Prior Period
- Revenue Decline: Semiconductor Test revenue dropped 53% ($399.3 million) year-over-year due to excess test capacity at customer sites resulting from the global economic downturn. Systems Test Group revenue increased 25% ($39.4 million), driven by Hard Disk Drive system sales.
- Margin Compression: Gross profit margin decreased by 12.2 percentage points to 33.9% for the nine-month period. This was driven by lower sales volume, product mix shifts, and a $10.9 million charge to adjust Eagle Test inventory to fair value.
- Restructuring Costs: The company recorded $36.5 million in restructuring charges for the nine months ended Oct 4, 2009, including $33.0 million for severance related to approximately 800 headcount reductions and $4.4 million for facility exits.
- Debt Restructuring: The company replaced its revolving credit facility with $190 million in 4.50% convertible senior notes due in 2014. This transaction included a convertible note hedge and warrant transaction.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the significant revenue decline to the global economic downturn and excess capacity in the semiconductor industry. Cost reduction initiatives, including workforce reductions and temporary salary cuts, helped offset some revenue declines. The company expects to pay approximately $3.4 million against lease accruals over the next twelve months.
Risks and Contingencies:
- Legal Proceedings: Ongoing patent infringement litigation with Xyratex Technology, Ltd. regarding disk drive test products. Teradyne has filed counterclaims and intends to vigorously defend the suit.
- Environmental Liability: Designated as a Potentially Responsible Party (PRP) for two clean-up sites in California related to prior acquisitions (Perception Laminates). Management believes potential losses are unlikely to be material to financial position but could impact results of operations in a single period.
- Valuation Allowance: The company maintains a valuation allowance for deferred tax assets in the U.S. and Singapore due to uncertainty regarding realization, which will not be reduced until sustained profitability is demonstrated.
Investor Verification Checklist
- Verify the sustainability of the revenue recovery in the Systems Test Group segment versus the continued decline in Semiconductor Test.
- Monitor the impact of the $190 million convertible senior notes on future interest expenses (effective rate approx. 14.5%) and potential dilution.
- Assess the timeline and cash impact of the remaining restructuring accruals ($10.7 million total, including $6.2 million for severance and $4.5 million for facilities).
- Review the status of the Xyratex patent litigation and potential financial exposure.
- Confirm the company's ability to reduce its valuation allowance on deferred tax assets as profitability stabilizes.